Lumos Pharma — Q1 2024 Earnings Presentation
14 slides from Lumos Pharma's earnings presentation, May 15, 2024
Slide 1: End-of-Phase 2 FDA Meeting Review, Clinical Update and Q1 2024 Financial Results
1 End-of-Phase 2 FDA Meeting Review Clinical Update Q1 2024 Financial Results May 15, 2024
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. that involve substantial risks and uncertainties. All such statements contained in this presentation are forward- looking statements within the meaning of The Private Securities Litigation Reform
Slide 3: Agenda
3 Agenda • Lisa Miller, Vice President of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • Lori Lawley, Chief Fina
Slide 4: Summary of Milestones and Additional Phase 2 Data
4 Summary of Milestones and Additional Phase 2 Data o Positive End-of-Phase 2 meeting with FDA supportive of registrational path forward • FDA recognized LUM-201, a growth hormone secretagogue, as a novel growth promoter • FDA acknowledged the use of a placebo-controlled clinical trial design as an
Slide 5: FDA End-of-Phase 2 Meeting Update
5 FDA End-of-Phase 2 Meeting Update Positive, constructive meeting with ~30 FDA staff in attendance Acknowledged that we are not a GH product – but a novel growth promotor Tone was collaborative and focused on approaches for a Phase 3 pivotal trial FDA suggested that a placebo-controlled Phase 3 tri
Slide 6: Summary Topline Phase 2 Data
6 Summary Topline Phase 2 Data o Topline Phase 2 data met all primary and secondary endpoints o PEM test was reproducible and predicted response to LUM-201 o Oral LUM-201 significantly increased growth rates from baseline o LUM-201 restored normal GH secretion and IGF-1 levels through increased ampl
Slide 7: Phase 3 Trial Design Options Discussed with the FDA
7 Phase 3 Trial Design Options Discussed with the FDA Lumos Submitted Non-Inferiority Study o LUM-201 vs rhGH control o 12-month duration o Non-inferiority margin o The lower bound of non-inferiority margin must be above the clinically meaningful AHV growth rate o LUM-201 vs placebo o 12-month durat
Slide 8: Placebo-Controlled Phase 3 Trial
8 12-month, 2:1 randomization, double-blind, single arm cross-over design with all placebo patients switched to LUM-201 at 6 months, who then continue for an additional 6 months on treatment Screening Up to 60 days LUM-201 1.6 mg/kg/day 12 months N ~100 Placebo control 6 months N= approximately 40 -
Slide 9: OraGrowtH210: LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets
9 OraGrowtH210: LUM-201 Growth Comparable to Multiple 12-Month Historical Datasets *Daily Genotropin control group for Somatrogon Ph3 dosed at 0.034 mg/kg/day (equates to 0.24 mg/kg/wk); subjects were stratified based on GH production during a standard stim test. JCEM Volume 107, Issue 7, July 2022,
Slide 10: OraGrowtH210: LUM-201 Produces Significant Increase in Growth from Baseline AHV
10 OraGrowtH210: LUM-201 Produces Significant Increase in Growth from Baseline AHV at 6 and 12 Months Per Protocol (PP) Baseline AHV was not required for enrollment; therefore, baseline AHVs shown represent available data from all OraGrowtH210 cohorts. AHV ANCOVA values represent an analysis of cova
Slide 11: LUM-201 Data Suggests Sustained Durability of Response vs SOC rhGH
11 LUM-201 Data Suggests Sustained Durability of Response vs SOC rhGH OraGrowtH210 & OraGrowtH212 Combined (1.6 and 3.2 mg/kg LUM-201) • Preliminary data demonstrated LUM-201 AHV durable to 24 months • More moderate year 2 AHV decline than rhGH likely due to LUM-201 restoration of GH and IGF-1 to no
Slide 12: Updated Phase 2 OraGrowtH Data to Be Presented in Q2 2024
12 Data Presentations o Pediatric Endocrine Society (PES) o Growth Hormone Research Society (GRS) o European Congress of Endocrinology (ECE) o Data presented at these medical conferences continue to demonstrate that by augmenting the natural pulsatile secretion of growth hormone, LUM-201 produces co
Slide 13: Lumos Pharma Pro Forma Financial Information as of March 31, 2024
13 Lumos Pharma Pro Forma Financial Information as of March 31, 2024 Values in USD LUMO Cash, cash equivalents, & short-term investments to support operations through Q3 2024, inclusive of Phase 3 planning and preparatory activities. Q1 2024 R&D Expense $7.2M G&A Expense $3.8M Net Loss $10.4M Cash &
Slide 14: Investment Thesis
14 • Positive End-of-Phase 2 meeting with FDA held early Q2 2024 regarding Phase 3 program • Initiation of Phase 3 trial anticipated Q4 2024 • PEM strategy de-risks patient selection, identifying likely LUM-201 responders** • Phase 2 trials met all primary and secondary endpoints • Phase 2 data demo